Data / Research funding / Provincial Health Services Authority
Provincial Health Services Authority: 5 NIH awards ($8.5M), fiscal years 2021 to 2026
Provincial Health Services Authority in Vancouver is funded under 5 NIH awards ($8.5M) in the NIH and NSF award files, read 2026-11-03. NIH fiscal years 2021 to 2025; NSF fiscal years 2022 to 2026.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
Awards
5 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|
| Comparative Modeling of Lung Cancer Prevention, Early Detection and Treatment Interventions | NIH | National Cancer Institute | 2022 to 2025 | $4,678,848 | December 3, 2022 | August 31, 2026 | MEZA, RAFAEL | reporter.nih.gov |
| Structure, function, and application of novel antagonists of the intrinsically disordered androgen receptor amino-terminal domain as imaging agents and therapeutics | NIH | National Cancer Institute | 2021 to 2025 | $2,182,643 | July 13, 2021 | June 30, 2027 | SADAR, MARIANNE D | reporter.nih.gov |
| Integrating investigational miR371a-3p with conventional radiology imaging for earlier and more precise detection of active germ cell malignancy: A BCC/SWOG/S1823 secondary use of data collaboration. | NIH | National Cancer Institute | 2022 to 2024 | $1,177,509 | April 1, 2022 | March 31, 2026 | NAPPI, LUCIA | reporter.nih.gov |
| Delineating the mechanisms of androgen receptor activation function-1 antagonists for development of novel prostate cancer therapeutics | NIH | National Cancer Institute | 2021 | $275,849 | April 1, 2004 | January 31, 2023 | SADAR, MARIANNE D | reporter.nih.gov |
| De Novo Assembly Tools: Research with Unbiased Engines - Renewal (DNA-TRUER) | NIH | National Human Genome Research Institute | 2022 | $191,280 | March 10, 2022 | March 31, 2023 | BIROL, INANC | reporter.nih.gov |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|
| 2025 | 2 | $2,000,785 | 0 | $0 |
| 2024 | 2 | $794,830 | 0 | $0 |
| 2023 | 3 | $2,343,725 | 0 | $0 |
| 2022 | 4 | $2,648,220 | 0 | $0 |
| 2021 | 2 | $718,569 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|
| NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed) | PAR-27-089 | NIH | 93.395 | November 2, 2026 | Not listed | Same assistance listing 93.395 as 1 award here |
| Developing novel theory and methods for understanding the genetic architecture of complex human traits (R01 Clinical Trial Not Allowed) | PAR-25-255 | NIH | 93.172 | November 5, 2026 | Not listed | Same assistance listing 93.172 as 1 award here |
| Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed) | PAR-25-095 | NIH | 93.172 | November 6, 2026 | $350,000 | Same assistance listing 93.172 as 1 award here |
| Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) | RFA-CA-27-001 | NIH | 93.394 | November 10, 2026 | $150,000 | Same assistance listing 93.394 as 1 award here |
| Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) | RFA-CA-27-002 | NIH | 93.394 | November 10, 2026 | $300,000 | Same assistance listing 93.394 as 1 award here |
| Precision Approaches in Radiation Synthetic Combinations (PAIRS, RP1 Clinical Trial Optional) | PAR-26-152 | NIH | 93.395 | November 11, 2026 | Not listed | Same assistance listing 93.395 as 1 award here |
| Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional) | PAR-25-370 | NIH | 93.172 | November 16, 2026 | $50,000 | Same assistance listing 93.172 as 1 award here |
| Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed) | PAR-25-096 | NIH | 93.172 | November 17, 2026 | $200,000 | Same assistance listing 93.172 as 1 award here |
| Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional) | PAR-25-369 | NIH | 93.172 | November 18, 2026 | Not listed | Same assistance listing 93.172 as 1 award here |
| Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional) | PAR-25-371 | NIH | 93.172 | November 18, 2026 | Not listed | Same assistance listing 93.172 as 1 award here |
| NCI Research Specialist Award for Core and Laboratory-based Scientists (R50 Clinical Trial Not Allowed) | PAR-27-088 | NIH | 93.395 | November 20, 2026 | Not listed | Same assistance listing 93.395 as 1 award here |
| Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional) | PA-23-317 | NIH | 93.394 | November 24, 2026 | Not listed | Same assistance listing 93.394 as 1 award here |
| Emerging Global Leader Award (K43 Independent Clinical Trial Required) | PAR-24-295 | NIH | 93.172 | December 3, 2026 | Not listed | Same assistance listing 93.172 as 1 award here |
| Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed) | PAR-24-296 | NIH | 93.172 | December 3, 2026 | Not listed | Same assistance listing 93.172 as 1 award here |
| NIH Research Software Engineer (RSE) Award (R50 Clinical Trials Not Allowed) | RFA-OD-24-011 | NIH | 93.396 | December 4, 2026 | Not listed | Same assistance listing 93.396 as 1 award here |
| Systematic Characterization of Genomic Variation to Assess Effects of Individual Variants on Genome Function and Phenotype (UM1 Clinical Trials Not Allowed) | RFA-HG-27-007 | NIH | 93.172 | December 14, 2026 | $2 million | Same assistance listing 93.172 as 1 award here |
| IGVF Data and Coordinating Center (U24 Clinical trials Not Allowed) | RFA-HG-27-008 | NIH | 93.172 | December 14, 2026 | $4 million | Same assistance listing 93.172 as 1 award here |
| Genomic Variant Interactions With Other Variants Or The Environment (UM1 Clinical Trials Not Allowed) | RFA-HG-27-009 | NIH | 93.172 | December 14, 2026 | $1.5 million | Same assistance listing 93.172 as 1 award here |
| Computational Modeling and Analysis of the Impact of Genomic Variation on Function (UM1, Clinical Trial Not Allowed) | RFA-HG-27-010 | NIH | 93.172 | December 14, 2026 | $800,000 | Same assistance listing 93.172 as 1 award here |
| Small Business Transition Grant for New Entrepreneurs (Parent R43/R44 Clinical Trial Optional) | PAR-27-039 | NIH | 93.172 | January 5, 2027 | Not listed | Same assistance listing 93.172 as 1 award here |
Topics of its NIH awards
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.